28 Apr, 2026

AI-Assisted Drug Discovery: Why Governed Data Is the Rate Limiter, Not Model Capability

Executive Summary (TL;DR) AI-assisted drug discovery is transforming pharmaceuticals, but data governance is often neglected. Governed data is essential for successful and ethical AI implementation in healthcare. Unstructured and poorly governed data leads to misinformation and inefficiencies in drug discovery. The full framework for securing healthcare AI and data is available in our The Architecture […]

6 mins read

Architectural Constraints and Failure Modes in AI-Driven Drug Discovery Programs

Executive Summary (TL;DR) AI-driven drug discovery failures are rarely algorithmic first. Data validity, measurement bias, and biological misalignment break earlier. Binding affinity predictions do not equate to therapeutic effect. Misinterpreting this distinction propagates costly false positives. Model interpretability constraints directly affect regulatory defensibility, reproducibility, and cross-team adoption. Infrastructure complexity emerges from data heterogeneity, not scale […]

8 mins read

Beyond Storage: Building a Data Fabric for AI-Driven Drug Discovery

The “Silo” Problem Data fragmentation is the number one blocker for AI adoption in Pharma. Even industry giants like Novartis have publicly noted the extreme difficulty of cleaning and linking heterogeneous data across a global organization. Valuable data sits trapped in different formats (structured SQL vs. unstructured pathology images), different legacy applications (old ELNs vs. […]

1 min read

Why You Don’t Need a “Big Pharma” Budget for Quantum Drug Discovery

The Cost Barrier is Gone For decades, high-fidelity molecular modeling was a luxury reserved for the “Big Pharma” elite. Developing a new drug costs nearly $2 billion, and a significant portion of that budget goes into massive High-Performance Computing (HPC) clusters required to run complex simulations. Small biotechs and startups were forced to rely on […]

2 mins read

AI Data Management for Drug Discovery: Accelerating R&D with Solix EAI Pharma

What is AI Data Management in Life Sciences? We are living in the “Decade of Data.” The biomedical domain has seen an explosion of information, driven by the plummeting cost of Next Generation Sequencing (NGS), the digitization of health records, and the rise of wearable sensors. However, for most Pharma organizations, this data is a […]

2 mins read

Why GenAI Fails in Drug Discovery and How Semantic Data Fixes It

Introduction: The Promise vs. The Reality of Pharma AI The pharmaceutical industry is currently navigating a paradoxical “drug drought.” Over the last decade, R&D investment has skyrocketed, yet the return on investment (ROI) for the top pharmaceutical companies has plummeted dropping from roughly 10% in 2010 to under 2% recently. The industry is desperate for […]

3 mins read